- Home
- PARK vs ESLA Comparison
PARK vs ESLA Comparison
Compare PARK & ESLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PARK | ESLA |
|---|---|---|
| Founded | 1972 | 2021 |
| Country | United States | United States |
| Employees | 1212 | N/A |
| Industry | Misc Health and Biotechnology Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 81.0M | 69.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PARK | ESLA |
|---|---|---|
| Price | $17.70 | $1.68 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 10.4K | ★ 165.7K |
| Earning Date | 05-13-2026 | 05-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.06 | N/A |
| Revenue Next Year | $6.17 | N/A |
| P/E Ratio | $6.47 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.29 | $0.78 |
| 52 Week High | $21.60 | $3.15 |
Technical Indicators
Market Signals| Indicator | PARK | ESLA |
|---|---|---|
| Relative Strength Index (RSI) | 49.13 | 56.20 |
| Support Level | $15.56 | $1.48 |
| Resistance Level | $17.69 | $2.07 |
| Average True Range (ATR) | 0.61 | 0.17 |
| MACD | -0.05 | -0.03 |
| Stochastic Oscillator | 19.61 | 48.01 |
Price Performance
Historical ComparisonAbout PARK Park Dental Partners Inc.
Park Dental Partners Inc is a dental resource organization (DRO) operating through its subsidiary. It Provides comprehensive business support services including clinical team members, administrative personnel, facilities and equipment to its affiliated general and multi-specialty dental practices throughout Minnesota and Wisconsin. Its network of affiliated dental practices provides both general and specialty dental services, including oral surgery, periodontics, pediatric dentistry, prosthodontics, endodontics, and orthodontics, under long-term agreements with initial terms of 30-years, with automatic 5-year renewals.
About ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors.